A CXC Motif Ligand 10 Polymorphism as a Marker to Predict Severity of Graves' Disease-Reference-Cited by-同舟云学术

A CXC Motif Ligand 10 Polymorphism as a Marker to Predict Severity of Graves' Disease

Published:2010-03 Issue:3 Volume:20 Page:343-345
ISSN:1050-7256
Container-title:Thyroid
language:en
Short-container-title:Thyroid

Author:

Brück Patrick¹,Bartsch Wiebke²,Sadet Dilek²,Penna-Martinez Marissa²,Kurylowicz Alina³,Bednarczuk Tomasz³,Robbers Inka²,Paunkovic Jane⁴,Böhme Angelika²,Badenhoop Klaus²,Ramos-Lopez Elizabeth²

Affiliation:

1. Division of Haematology and Oncology, Department of Internal Medicine IV, University Hospital Giessen and Marburg, Giessen, Germany.

2. Division of Endocrinology, Diabetes, and Metabolism, Department of Internal Medicine I, University Hospital Frankfurt, Frankfurt am Main, Germany.

3. Department of Endocrinology, Medical Research Center, Polish Academy of Science, Warsaw, Poland.

4. Department of Nuclear Medicine, Medical Center Zajecar, Zajecar, Serbia.

Publisher

Mary Ann Liebert Inc

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.liebertpub.com/doi/pdf/10.1089/thy.2009.0222

Reference22 articles.

1. Graves' Disease

2. Relationship between Disease Duration and Predominant Orbital T Cell Subset in Graves' Ophthalmopathy

3. TSH-R expression and cytokine profile in orbital tissue of activevs.inactive Graves’ ophthalmopathy patients

4. Cellular immune responses in autoimmune thyroid disease

5. Differential Expression of Chemokine Receptors and Chemotactic Responsiveness of Type 1 T Helper Cells (Th1s) and Th2s

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel therapies for thyroid autoimmune diseases: An update;Best Practice & Research Clinical Endocrinology & Metabolism;2020-01

2. Increased expression of hub gene CXCL10 in peripheral blood mononuclear cells of patients with systemic lupus erythematosus;Experimental and Therapeutic Medicine;2019-09-17

3. Novel Therapies for Thyroid Autoimmune Diseases;Expert Review of Clinical Pharmacology;2016-03-08

4. Application of Agents Against Interferon-Gamma-Dependent Chemokines in Immunotherapy;Letters in Drug Design & Discovery;2015-09-09

5. Targeting Chemokine (C-X-C motif) Receptor 3 in Thyroid Autoimmunity;Recent Patents on Endocrine, Metabolic & Immune Drug Discovery;2014-07-31